Lance Alstodt - Jun 15, 2022 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
President, CEO, COB, Director
Signature
/s/ Lance Alstodt
Stock symbol
BRTX
Transactions as of
Jun 15, 2022
Transactions value $
$2,578
Form type
4
Date filed
6/15/2022, 05:30 PM
Previous filing
Jun 15, 2022
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRTX Common Stock Purchase $2.58K +700 +0.39% $3.68 180K Jun 15, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BRTX Stock Option 293K Jun 15, 2022 Common Stock 293K $13.50 Direct F3
holding BRTX Stock Option 42.1K Jun 15, 2022 Common Stock 42.1K $13.50 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $3.655 to $3.7167 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
F2 Includes 108,191 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on June 18, 2022, August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
F3 The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F4 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.